By Sneha S K and Sahil Pandey
Dec 31 (Reuters) - The U.S. Food and Drug Administration has declined to approve Corcept Therapeutics' drug for the treatment of a rare hormonal disorder, the company said on Wednesday.
Shares of the drugmaker were down 48% at $36.41.
The company said the FDA could not arrive at a favorable benefit-risk assessment for the hormone-blocking oral treatment, known as relacorilant, without Corcept providing additional evidence of effectiveness.
The company was seeking approval for relacorilant as a treatment for patients with hypertension secondary to hypercortisolism.
"FDA's request for additional data may require additional trials, significantly dimming Corcept's outlook in Cushings," said Truist analyst Joon Lee.
Hypercortisolism, also known as Cushing's syndrome, occurs when the body is exposed to high cortisol activity.
Corcept had submitted trial data that showed that relacorilant made improvements in a wide array of hypercortisolism's signs and symptoms.
"We will meet with the FDA as soon as possible to discuss the best path forward," said Joseph Belanoff, Corcept's CEO.
Main symptoms of hypercortisolism include a fatty hump between the shoulders, a rounded face, and pink or purple stretch marks on the skin. People with Cushing's also experience diabetes, high blood pressure, muscle weakness and immune suppression.
Relacorilant is a selective cortisol modulator designed to block the effects of cortisol, while avoiding certain off‑target hormonal effects.
"Given the company had opportunities to address FDA's concerns during mid and late-stage reviews, it's unclear if any further dialogue can resolve the review issues without additional trials," Lee added.
Corcept is also studying the drug in a variety of serious disorders including ovarian and prostate cancer. Its other drug known as Korlym is approved to treat high blood sugar caused by hypercortisolism in adults with endogenous Cushing's syndrome.
Other approved treatments for Cushing's syndrome include Isturisa by Recordati and Xeris Biopharma's Recorlev.
(Reporting by Sahil Pandey and Sneha S K in Bengaluru; Editing by Shailesh Kuber)
latest_posts
- 1
Watch South Korean startup Innospace attempt its 1st-ever orbital launch today - 2IDF bans Android phones for senior officers, iPhones now mandatory, Army Radio reports
- 3Pulsars to the extreme: Spinning dead stars found blasting radio signals from the 'edge of their magnetic reach'
- 4Amazon sued over 'punitive' handling of employee absences
- 5Israel intensifies Lebanon attacks and hits areas not in Hezbollah's control
- Iran war drives global fertilizer prices up, raising food cost fears
- Best Streaming Gadget for Your Home Theater
- Lucky airplane passengers capture NASA's Artemis 2 moon launch from the sky
- Vote in favor of the juice that you love for its medical advantages!
- Iranian naval commander Alireza Tangsiri killed in attack, says Israel
- Dinosaur collagen used to create one-of-a-kind handbag
- Minute Maid’s frozen juice concentrate is ending after 80 years — and so is a certain kind of kitchen ritual
- Malaysia To Revive Search for Missing Flight MH370
- Opening Innovativeness: Moving Thoughts and Tasks
